Prevalence of genotypic resistance in untreated HIV-infected patients

Revista Espanola de Quimioterapia

Volumn 17, Issue 3, 2004, Pages 250-256

  Eiros Bouza, José María ^a,e   Blanco, R ^a   Labayru, C ^b   Hernandez B ^c   Bou, G ^d   Dominguez Gil M ^a   Ortiz De Lejarazu, R ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Genotypic resistance; HIV; Naive

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; SPAIN; VIRUS RESISTANCE;

DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREVALENCE; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 9644287798     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hecht, F.M., Grant, RM., Petropoulos, C.J. et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. New Engl J Med 1998; 339: 307-311.
2. Yerly, S., Kaiser, L., Race, E., Bru, J.P., Clavel, F., Perrin, L. Transmission of antirretroviral-drug resistant HIV-1 variants. Lancet 1999; 354: 729-733.
3. Little, S.J., Daar, E.S., D'Aquila, R.T. et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. J Am Med Assoc 1999; 282: 1142-1149.
4. Boden, D., Hurley, A., Zhang, L. et al. HIV-1 drug resistance in newly infected individuals. J Am Med Assoc 1999; 282: 1135-1141.
5. Simonds, R.J., Holmberg, S.D., Hurwitz, R.L. et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. New Engl J Med 1992; 236: 726-732.
6. Antela, A., Iribarren, J.A., Clotet, B., Guerra, L. Documentas de consenso y guí'as clínicas sobre resistencias a antirretrovirales. Enferm Infecc Microbiol Clín 2001; 19: 47-52.
7. Ledesma, E., Soriano, V. Conferencia de consenso española sobre los test de resistencia a antirretrovirales en la práctica clínica. AIDS 1999; 13: 1998-2001.
8. Hirsch, M.S., Conway, B., D'Aquila, R.T. et al., for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. J Am Med Assoc 1998; 279: 1984-1991.
9. Hirsch, M.S., Brun-Vézinet, F., D'Aquila, R.T. et al. Antiretroviral drug resistance testing in adults with HIV infection. Recommendations of an International AIDS Society-USA panel. J Am Med Assoc 2000; 283: 2417-2425.
10. Miller, V., Vandamme, A.M., Loveday, C. et al., on behalf of The Euroguidelines group for HIV drug resistance testing. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of treatment management: Recommendations for the European setting. AIDS 2001; 15: 309-320.
11. Miró, J., Antela, A., Arrizabalaga. J. et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecta al tratamiento antirretroví rico en pacientes adultes infectados por el virus de la inmuno-deficiencia humana en el año 2000 (II). Enferm Infecc Microbiol Clín 2000; 18: 329-351.
12. Miró, J.M., Antela, A., Arrizabalaga, J. et al. Recomendaciones de GESIDA/Plan Nadonal sobre el Sida respecta al tratamiento antirretroví rico en pacientes adultes infectados par virus de la inmunodeficiencia humana en el año 2000 (II). Enferm Infecc Microbiol Clín 2000; 18; 396-412.
13. Versant® HIV-1 RT. Kit for the simultaneous detection of wild-type sequences and mutations at several locations in the HIV-1 reverse transcriptase gen. Bayer Corporation, Turrytown, NY. USA.
14. Versant® HIV-1 protease. Kit for the simultaneous detection of wildtype and mutations at codons 30, 46/48, 50, 54, 82/84, and 90 in the HIV-1 protease region of the pol gene. Bayer Corporation, Turrytown, NY, USA.
15. a ed. TAISA, Barcelona 2002; 1-17.
16. GuideLines Rules 6.0 © Visible Genetics Inc. 2001-2002.
17. TM Version 1.6.2 © Virco Central Virological Laboratory. Ireland 2002.
18. American Society of Health-System Pharmacists® ("ASHP"). Bethesda, Maryland 20814, USA.
19. http://hiv.medscape.com/updates/quickguide
20. Domènech, J.M., Bonillo, A. Proceso de datas sanitarios con el Sistema SPSS. Documentas del Laboratorio de Estadística Aplicada y Modelización. Universidad Autónoma de Barcelona, Barcelona 1998.
21. Castilla, J., De la Fuente, L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de Sida en Espana: 1980-1998. Med Clín (Bare) 2000; 115: 85-89.
22. Echevarria, J.E., Echevarría, J.M. Diseño de métodos de PCR de aplicaciones en diagnóstico: Principios generales. In: Institute de Salud Carlos III, Ministerio de Sanidad y Consumo (Ed.). Teoría y Práctica de la PCR en Virología humana. Litofinter, Madrid 1997; 25-36.
23. Kindelán, J.M., Giménez-Doménech, R., Vidal-Verdú, E., Madueño, J. and Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI). Prevalencia de tnutaciones pritnarias en el virus de la inmunodeficiencia humana que confieren resistencia a análogos de nucleósidos en pacientes de Andalucía no tratados previameitte. Med Clin (Barc) 2000; 115; 423-425.
24. Little, S.J. Is transmitted drug resistance in HIV on the rise? BMJ 2001; 322: 1074-1075.
25. Rubio, A., Leal, M., Pineda. J.A. et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-I-infected antiviral-naive patients from 1989 to 1996. AIDS 1997: 11: 1184-1186.
26. Guerrero, A, Canizares, A., Cartelle, M. et al. La resistencia a los fármacos antirretrovirales en pacientes no tratados es baja en Espana. Publicatión Oficial de SEISIDA 2001; 12 (Suppl. 1): 7.
27. Weinstock, H., Respess, R., Heneine, W. et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human iminunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J infect Dis 2000; 182: 330-333.
28. Horban, A., Stanczak, J.J., Bakowska, E. et al. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw Cohort. Infection 2002; 30: 356-359.
29. Salomon, H., Wainberg, M.A., Brenner, B. et al. Prevalence of HIV-I resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000; 14: F17-F23.
30. Wensing. A., Van de Vijveer, D., Asjo, B. et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: The CATCH study. 2nd IAS Conference on Pathogenesis and Treatment, Paris 2003; Abstr. LB1.
31. Puig, T., Pérez-Olmeda, M., Rubio, A. et al. Prevalence of genotypic resistance to nucteoside analogues and protease inhibitors in Spain. AIDS 2000; 14: 727-732.
32. Gomez-Cano, M., Rubio, A., Puig, T. et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1015-1020.
33. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087-1088.
34. Devereux, H.L., Youle, M., Johnson, M.A., Loveday, C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-F127.
35. Imamichi, H., Crandall, K.A., Natarajan, V et al. Human immunodeficiency virus type I quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001; 183: 36-50.
36. Ibe, S., Hotta, N., Takeo, U. et al. Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol Immunol 2003; 47: 499-505.
37. Loveday, C., MacRae, E., Johnson, M. A marked increase in prevalence of ART mutations in naive patients with HIV/SIDA in the UK in 2002 - Time to recommend resistance testing prior to therapy. 10th Conference on Retroviruses and Opportunistic Infections. Boston 2003: Abstr. 632.